GlassScriptPhysician profile
Suhail B Chaudhry
NPI 1467525584
$7,879.45
in general payments reported to CMS, 2019-2025
44 companies · $976 in 2025
The $976 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $1,069 · 2021: $1,316 · 2022: $1,073 · 2023: $649 · 2024: $779 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,392.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $891.30 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $779.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $761.19 | 2019-2025 | |
| Amgen INC. | $668.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $463.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.11 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $222.27 | 2019-2024 | |
| Glaxosmithkline, LLC. | $217.16 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $208.07 | 2019-2021 | |
| Amarin Pharma, INC. | $204.11 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.36 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $149.00 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $132.16 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $111.73 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhail Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.